India Pharma Outlook Team | Friday, 13 June 2025
Masimo, a global medical technology firm creating and delivering a wide array of industry-leading monitoring technologies, including new measures, sensors, patient monitors, and automation and connectivity solutions.
The findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women’s Medical University demonstrated the ability of electroencephalogram (EEG)-guided anesthesia, using Masimo SedLine Brain Function Monitoring, to improve anesthesia administration in children undergoing surgery.1 The researchers found that the use of SedLine led to a significant reduction in the amount of a commonly used inhalation anesthetic (sevoflurane) needed to maintain anesthesia in pediatric patients, reducing their exposure to the drug.
Also read: NVIDIA and Novo Nordisk Join Forces to Accelerate AI-Driven Drug Discovery
Pediatric anesthetic emergence delirium (PAED), which sometimes presents as disorientation, agitation, or hallucinations during recovery, was consequently far less common in the patients. Children under SedLine monitoring also regained consciousness more quickly and were able to be safely sent to the post-anesthesia care unit, or PACU, sooner than they would have under usual practice. The researchers pointed out that these time savings could potentially result in further cost savings. Overall, the researchers discovered that Masimo SedLine contributed to the safety, effectiveness, and cost-effectiveness of pediatric anesthesia.By reducing sevoflurane exposure, EEG-guided anesthesia employing Masimo technology dramatically decreased pediatric anesthetic emerging delirium, time to emergence and discharge, and cost of care. Children under SedLine monitoring had a 14% lower incidence rate of PAED and were exposed to an average of 1.4 MAC hours less sevoflurane.
, CDSCO.jpg)
